SINOPHARM GROUP 1/5/O.N. (X2S1) — Working Capital to Net Assets Ratio
SINOPHARM GROUP 1/5/O.N. (X2S1) has a Working Capital to Net Assets ratio of 74.6% as of December 2025. Working capital of €100.07 Billion (current assets of €346.80 Billion minus current liabilities of €246.73 Billion) is measured against net assets of €134.16 Billion. A higher ratio indicates strong short-term liquidity financed by the equity base. See X2S1 equity to assets ratio to measure how much of total assets are equity-financed.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
SINOPHARM GROUP 1/5/O.N. Working Capital to Net Assets (2021–2025)
This chart shows how SINOPHARM GROUP 1/5/O.N.'s Working Capital to Net Assets ratio has evolved across 5 annual periods from 2021 to 2025. As of December 2025, the ratio stands at 74.6%, reflecting working capital of €100.07 Billion against net assets of €134.16 Billion EUR. Check SINOPHARM GROUP 1/5/O.N. tangible net worth ratio to evaluate the tangible quality of the company's equity base.
Annual Working Capital to Net Assets for SINOPHARM GROUP 1/5/O.N. (2021–2025)
The table below presents the year-by-year Working Capital to Net Assets ratio for SINOPHARM GROUP 1/5/O.N. from 2021 to 2025, covering 5 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For live market cap and the full company profile, see X2S1 market cap.
| Year | WC/NA Ratio | Working Capital (EUR) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2025 | 74.6% | €100.07 Billion | €134.16 Billion | €346.80 Billion | €246.73 Billion | ▼ -2.0 pp |
| 2024 | 76.6% | €97.07 Billion | €126.69 Billion | €347.45 Billion | €250.38 Billion | ▼ -2.6 pp |
| 2023 | 79.2% | €95.34 Billion | €120.32 Billion | €336.84 Billion | €241.49 Billion | ▲ +2.5 pp |
| 2022 | 76.7% | €84.44 Billion | €110.07 Billion | €319.41 Billion | €234.96 Billion | ▲ +4.9 pp |
| 2021 | 71.9% | €71.62 Billion | €99.65 Billion | €290.92 Billion | €219.31 Billion | — |